relapsed advanced non-small cell lung cartinoma
Conditions
Interventions
Patients receive oral gefitinib 250mg and meloxicam 10mg once daily
Sponsors
Department of Medical Oncology Kinki University School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1)Histologically confirmed non-small lung cancer (2)With clinical organization object before treatment (3)Failed 1 or 2 prior treatment regimen for advanced non-small cell lung cancer. (4)Aged 20 and over. (5)Eastern Cooperative Oncology Group(ECOG) performance status 0-2 (6)With measurable lesion (7)Adequate hematologic, hepatic, and renal functions (8)No prior gefitinib (9)More than 30days since prior chronic nonsteroidal nanti-inflammatory drugs(NAISDs) (10)No history of peptic ulcer disease within the past 6 months (11)More than 2 weeks prior therapy (12)Life expectancy over 3 months (13)Provide written informed consent
Exclusion criteria
Exclusion criteria: (1)Uncontrolled infection, cardiac disease, hepatic disease, and so on (2)Evidence of interstitial lung disease in chest x-p (3)Active brain metastases (4)Other active malignancy (5)History of bone marrow transplantation (6)History of peripheral blood stem cell transplantation (7)Allergy to any drugs (8)Pregnant or nursing women (9)Patients don't have will of contraception (10)Uncontrolled diabetes (11)Other concurrent serious medical condition
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Response rate | — |
Countries
Japan
Outcome results
None listed